The therapeutic potential of cannabis

Lancet Neurology

Volumn 2, Issue 5, 2003, Pages 291-298

  Baker, David ^a   Pryce, Gareth ^a   Giovannoni, Gavin ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDINOYLGLYCEROL; 4 AMINOBUTYRIC ACID; AJULEMIC ACID; ANANDAMIDE; BENZODIAZEPINE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; CAPSAICIN; DEXANABINOL; DRONABINOL; GLUTAMIC ACID; GLYCINE; LEVONANTRADOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NABILONE; NEUROTRANSMITTER; NOLADIN ETHER; NORADRENALIN; OPIATE; PROTEIN DERIVATIVE; PSYCHOTROPIC AGENT; RECEPTOR BLOCKING AGENT; RIMONABANT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR; VIRODHAMINE; DRUG RECEPTOR;

AUTONOMIC NERVOUS SYSTEM; BLADDER DYSFUNCTION; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; LIPOPHILICITY; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NEUROBIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; PAIN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; REVIEW; SIDE EFFECT; SPASTICITY; BLADDER DISEASE; CHEMISTRY; MUSCLE SPASM; PHYSIOLOGY; PHYTOTHERAPY;

CANNABINOIDS; CANNABIS; CLINICAL TRIALS; HUMANS; PAIN; PHYTOTHERAPY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPASM; URINARY BLADDER DISEASES;

EID: 0041534429     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00381-8     Document Type: Review

References (78)

1. The United Kingdom Parliament House of Lords. Science and Technology: Ninth Report. http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ ldselect/ldsctech/151/15101.htm (accessed April 1, 2003).
2. Mechoulam R. The pharmacohistory of Cannabis sativa. Mechoulam R. Cannabinoids as therapeutic agents. 1986;1-19 Boca Raton, CRC Press.
3. Schnelle M., Grotenhermen F., Reif M., Gorter R.W. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementärmed. 6:(suppl 3):1999;28-36.
4. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 38:1997;44-48.
5. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol Ther. 95:2002;165-174.
6. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 56:2001;1059-1068.
7. Hawks R.L. The constituents of cannabis and the disposition and metabolism of cannabinoids. NIDA Res Monogr. 42:1982;125-137.
8. Zuarsi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of anti-psychotic activity. Psychopharmacology. 104:1991;260-264.
9. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
10. Howlett A.C., Barth F., Bonner T.I., et al. International Union of Pharmacology: XXVII, classification of cannabinoid receptors. Pharmacol Rev. 54:2002;161-202.
11. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
12. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids. 66:2002;123-142.
13. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 74:1997;129-180.
14. Wiley J.L., Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids. 121:2002;57-63.
15. Brooks J.W., Pryce G., Bisogno T., et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol. 439:2002;83-92.
16. Barann M., Molderings G., Bruss M., Bonisch H., Urban B.W., Gothert M. Direct inhibition by cannabinoids of human 5-HT(3A) receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 137:2002;589-596.
17. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
18. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
19. Walker J.M., Krey J.F., Chu C.J., Huang S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids. 121:2002;159-172.
20. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
21. Sugiura T., Kobayashi Y., Oka S., Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids. 66:2002;173-192.
22. Hogestatt E.D., Zygmunt P.M. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids. 66:2002;343-351.
23. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids. 66:2002;201-210.
24. Dinh T.P., Freund T.F., Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 121:2002;149-158.
25. Wilson R.I., Nicoll R.A. Endocannabinoid signalling in the brain. Science. 296:2002;678-682.
26. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 2:1999;358-363.
27. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57:2001;2108-2111.
28. Degenhardt L., Hall W. Cannabis and psychosis. Curr Psychiatry Rep. 4:2002;191-196.
29. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 156:2002;319-327.
30. Kim D., Thayer S.A. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci. 21:2001;RC146.
31. Marsicano G., Wotjak C.T., Azad S.C., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418:2002;530-534.
32. Walker J., Huang S. Cannabinoid analgesia. Pharmacol Ther. 95:2002;127-135.
33. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 121:2002;173-190.
34. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
35. Baker D., Pryce G., Croxford J.L., et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2002;84-87.
36. Baker D., Pryce G., Croxford J.L., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
37. Walker J.M., Huang S.M. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids. 66:2002;235-242.
38. Lastres-Becker I., Fezza F., Cebeira M., et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport. 12:2001;2125-2129.
39. DiMarzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14:2000;1432-1438.
40. Schabitz W.R., Giuffrida A., Berger C., et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke. 33:2002;2112-2114.
41. Fowler C.J. Intravesical treatment of overactive bladder. Urology. 55:(suppl 5A):2000;60-64.
42. Martin R.S., Luong L.A., Welsh N.J., Eglen R.M., Martin G.R., MacLennan S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol. 129:2000;1707-1715.
43. Lever I.J., Malcangio M. CB1 receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br J Pharmacol. 135:2002;21-24.
44. Fox P., Thompson A., Zajicek J. A multicentre randomised controlled trial of cannabinoids in multiple sclerosis. J Neurol Sci. 187:2001;S453.
45. Bolla K.I., Brown K., Eldreth D., Tate K., Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology. 59:2002;1337-1343.
46. Whittle B.A., Guy G.W., Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther. 1:2001;183-205.
47. Mattes R.D., Shaw L.M., Edling-Owens J., Engelman K., Elsohly M.A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav. 44:1993;745-747.
48. Campbell F.A., Tramer M.R., Carroll D., Reynolds D.J., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 323:2001;13-16.
49. Notcutt W., Price M., Blossfeldt P., Chapman G. Clinical experience of the synthetic cannabinoid nabilone for chronic pain. Nahas G.G., Sutin K.M., Harvey D., Agurell S. Marihuana and medicine. 1999;567-572 Totowa, Humana Press.
50. Notcutt W, Price M, Sansom C, Simmons S, Phillips C. Medicinal cannabis extract in chronic pain: overall results of 29 "N of 1" studies (CBME-1). In: Symposium on the cannabinoids. http://www.cannabinoidsociety.org/ progab2.pdf (accessed April 1, 2003): 55.
51. Killestein J., Hoogervorst E.L., Reif M., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 58:2002;1404-1407.
52. Vaney C, Jobin P, Tscopp F, Heinzel M, Schnelle, M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis. In: Symposium on the cannabinoids http://www.cannabinoidsociety.org/progab2.pdf (accessed April 1, 2003): 57.
53. Brady C.M., Das Gupta R., Wiseman O.J., Dalton C.M., Berkley K.J., Fowler C.J. The effects of cannabis based medicinal extracts on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J Neurol Neurosurg Psych. 72:2002;139.
54. Robson PJ, Wade DT, Makela PM, House H.Cannabis medicinal extracts (CME), including cannabidiol, alleviated neurogenic systems in patients with multiple sclerosis and spinal cord injury. In: Symposium on the cannabinoids. http://www.cannabinoidsociety.org/progab2.pdf (accessed April 31, 2003): 56.
55. GW Pharmaceuticals. GW announces positive results from each of four phase three clinical trials. http://www.gwpharm.com/news_pres_05_nov_02.html (accessed April 1, 2003).
56. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 97:2000;505-519.
57. Lastres-Becker I., Hansen H.H., Berrendero F., et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse. 44:2002;23-35.
58. Bjartmar C., Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 14:2001;271-278.
59. Fowler C.J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, 'entourage'compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Brain Res Rev. 41:2003;26-43.
60. Grundy R.I. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs. 11:2002;1365-1374.
61. Nagayama T., Sinor A.D., Simon R.P., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 19:1999;2987-2995.
62. Panikashvili D., Simeonidou C., Ben-Shabat S., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:2001;527-531.
63. Pryce G, Hankey D, Ahmed Z, Baker, D. Cannanbinoid treatment and CB1 receptor involvement in inflammatory disease in the CNS. In: Symposium on the cannabinoids. http://www.cannabinoidsociety.org/progab2.pdf (accessed April 1, 2003): 50.
64. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis. 5:1998;534-551.
65. Muller-Vahl K.R., Schneider U., Koblenz A., et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 35:2002;57-61.
66. Hampson A.J., Grimaldi M., Lolic M., Wink D., Rosenthal R., Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 899:2000;274-282.
67. Knoller N., Levi L., Shoshan I., et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 30:2002;548-554.
68. Agurell S, Halldin M, Lindgren J-E, et al. Pharmacokinetics and metabolism of 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev1986; 38:21-43.69.
69. Grotenhermen F. Some practice-relevant aspects of the pharmacokinetics of THC. Forsch Komplementarmed. 6:(suppl 3):1999;37-39.
70. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 21:(suppl 8 & 9):1981;320-326.
71. Huestis M.A., Gorelick D.A., Heishman S.J., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 58:2001;322-328.
72. Sim-Selley L.J., Martin B.R. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-naphthalenyl)methanonemesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther. 303:2002;36-44.
73. Kathuria S., Gaetani S., Fegley D., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 9:2003;76-81.
74. Calignano A., Katona I., Desarnaud F., et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 408:2000;96-101.
75. Jarvinen T., Pate D., Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther. 95:2002;203-220.
76. Burstein S.H. Ajulemic acid (CT3): a potent analogue of the acid metabolites of THC. Curr Pharm Des. 6:2000;1339-1345.
77. Whelan J. New cannabinoid for multiple sclerosis. Drug Discov Today. 7:2002;745-746.
78. Thompson A.J., Baker D. Cannabinoids in MS; potentially useful but not just yet. Neurology. 58:2002;1323-1324.